A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

HER2-positive breast cancer has long proven to be a clinically distinct class of breast cancers for which several targeted therapies are now available. However, resistance to the treatment associated with specific gene expressions or mutations has been observed, revealing the underlying diversity of these cancers. Therefore, understanding the full extent of the HER2-positive disease heterogeneity still remains challenging. Here we carry out an in-depth genomic characterization of 64 HER2-positive breast tumour genomes that exhibit four subgroups, based on the expression data, with distinctive genomic features in terms of somatic mutations, copy-number changes or structural variations. The results suggest that, despite being clinically defined by a specific gene amplification, HER2-positive tumours melt into the whole luminal–basal breast cancer spectrum rather than standing apart. The results also lead to a refined ERBB2 amplicon of 106 kb and show that several cases of amplifications are compatible with a breakage–fusion–bridge mechanism.

[1]  F. Bertucci,et al.  A refined molecular taxonomy of breast cancer , 2011, Oncogene.

[2]  Kenny Q. Ye,et al.  Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.

[3]  T. Meehan,et al.  An atlas of active enhancers across human cell types and tissues , 2014, Nature.

[4]  M. Ringnér,et al.  High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer , 2010, Breast Cancer Research.

[5]  Simon Tavaré,et al.  beadarray: R classes and methods for Illumina bead-based data , 2007, Bioinform..

[6]  B. Mcclintock,et al.  The Stability of Broken Ends of Chromosomes in Zea Mays. , 1941, Genetics.

[7]  C. Greenman,et al.  Modeling the evolution space of breakage fusion bridge cycles with a stochastic folding process , 2015, Journal of Mathematical Biology.

[8]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[9]  Nikolas von Bubnoff,et al.  Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib , 2011, PloS one.

[10]  A. Børresen-Dale,et al.  Analyzing cancer samples with SNP arrays. , 2012, Methods in molecular biology.

[11]  David G. Knowles,et al.  Fast Computation and Applications of Genome Mappability , 2012, PloS one.

[12]  P. Fasching,et al.  HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer , 2013, Breast Cancer Research.

[13]  L. Pusztai,et al.  Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  A. Vincent-Salomon,et al.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.

[15]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Baselga,et al.  Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. P. Benzécri,et al.  Sur le calcul des taux d'inertie dans l'analyse d'un questionnaire, addendum et erratum à [BIN. MULT.] , 1979 .

[18]  Jörg Rahnenführer,et al.  Robert Gentleman, Vincent Carey, Wolfgang Huber, Rafael Irizarry, Sandrine Dudoit (2005): Bioinformatics and Computational Biology Solutions Using R and Bioconductor , 2009 .

[19]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[20]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[21]  Vineet Bafna,et al.  An algorithmic approach for breakage-fusion-bridge detection in tumor genomes , 2013, Proceedings of the National Academy of Sciences.

[22]  Carsten Denkert,et al.  PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[24]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[25]  E. Perez,et al.  Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Hua Guo,et al.  PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. , 2010, The American journal of pathology.

[27]  Hongjuan Zhao,et al.  TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.

[28]  N. Carter,et al.  Estimation of rearrangement phylogeny for cancer genomes. , 2012, Genome research.

[29]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[30]  Aleix Prat Aparicio.  Comprehensive molecular portraits of human breast tumours , 2012 .

[31]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[32]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[34]  I. Ial,et al.  Nature Communications , 2010, Nature Cell Biology.

[35]  Andrew Menzies,et al.  Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. , 2007, Genome research.

[36]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[37]  Y. Benjamini,et al.  Summarizing and correcting the GC content bias in high-throughput sequencing , 2012, Nucleic acids research.

[38]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[39]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[40]  Johan Staaf,et al.  Normalization of Illumina Infinium whole-genome SNP data improves copy number estimates and allelic intensity ratios , 2008, BMC Bioinformatics.

[41]  M. Espié,et al.  6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[42]  M. Greenacre,et al.  Multiple Correspondence Analysis and Related Methods , 2006 .

[43]  Jan de Leeuw,et al.  Interpreting multiple correspondence analysis as a multidimensional scaling method , 1992 .

[44]  Simen Myhre,et al.  The importance of gene-centring microarray data. , 2010, The Lancet. Oncology.

[45]  Carlos Caldas,et al.  TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance , 2014, Clinical Cancer Research.

[46]  Rafael A. Irizarry,et al.  Bioinformatics and Computational Biology Solutions using R and Bioconductor , 2005 .

[47]  David Haussler,et al.  Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons. , 2013, Cancer research.

[48]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[49]  Zoltan Szallasi,et al.  Jetset: selecting the optimal microarray probe set to represent a gene , 2011, BMC Bioinformatics.

[50]  Hisashi Tanaka,et al.  A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications , 2012, Breast Cancer Research.

[51]  D. Berry,et al.  Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Daniel Rios,et al.  Bioinformatics Applications Note Databases and Ontologies Deriving the Consequences of Genomic Variants with the Ensembl Api and Snp Effect Predictor , 2022 .

[53]  Lovelace J. Luquette,et al.  Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes , 2013, Cell.

[54]  Vineet Bafna,et al.  Reconstructing Breakage Fusion Bridge Architectures Using Noisy Copy Numbers , 2014, RECOMB.

[55]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[56]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[57]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[58]  Daniel Birnbaum,et al.  Genome profiling of ERBB2-amplified breast cancers , 2010, BMC Cancer.

[59]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[60]  C. Perou,et al.  Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer , 2014, Journal of the National Cancer Institute.

[61]  Achim Rody,et al.  T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers , 2009, Breast Cancer Research.

[62]  M. Espié,et al.  Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  A. Laenkholm,et al.  PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[66]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[68]  E. Barillot,et al.  Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays , 2009, Genome Biology.

[69]  C. Greenman.  Estimation of Rearrangement Phylogeny in Cancer , 2012 .

[70]  P. Campbell,et al.  OncoCis: annotation of cis-regulatory mutations in cancer , 2014, Genome Biology.

[71]  R. Bernards,et al.  PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  Jean Thioulouse,et al.  ADE-4: a multivariate analysis and graphical display software , 1997, Stat. Comput..